Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison

Overview of attention for article published in Experimental Hematology & Oncology, December 2013

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#41 of 296)
Good Attention Score compared to outputs of the same age (79th percentile)

Mentioned by

policy: 2 policy sources

Citations

dimensions_citation: 34 Dimensions

Readers on

mendeley: 41 Mendeley

Summary Policy documents Dimensions citations

So far, Altmetric has seen 4 policy documents that reference this research output.

Lutathera for Gastroenteropancreatic neuroendocrine tumors – Details

Cited by Canadian Agency for Drugs and Technologies in Health on 01 Jun 2023

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Siponimod for treating secondary progressive multiple sclerosis : Appraisal consultation committee papers

Cited by National Institute for Health and Care Excellence on 17 Jun 2020

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Lutathera for Gastroenteropancreatic neuroendocrine tumors – Details

Cited by Canadian Agency for Drugs and Technologies in Health on 01 Aug 2019

Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia : Appraisal consultation committee papers

Cited by National Institute for Health and Care Excellence on 19 Oct 2018

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.